Association of plasma ceramide with decline in kidney function in patients with type 2 diabetes

Circulating ceramide levels are dysregulated in kidney disease. However, their associations with rapid decline in kidney function (RDKF) and end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) are unknown. In this prospective study of 1746 T2D participants, we examined the association of plasma ceramide Cer16:0, Cer18:0, Cer24:0, and Cer24:1 with RDKF, defined as an estimated glomerular filtration rate (eGFR) decline of 5 ml/ min/1.73 m² per year or greater, and ESKD defined as eGFR <15/min/1.73 m² for at least 3 months, on dialysis or renal death at follow-up. During a median follow-up period of 7.7 years, 197 patients experienced RDKF. Ceramide Cer24:0 (odds ratio [OR] ¼ 0.71, 95% CI 0.56–0.90) and ratios Cer16:0/Cer24:0 (OR ¼ 3.54 [1.70–7.35]), Cer18:0/Cer24:0 (OR ¼ 1.89 [1.10–3.25]), and Cer24:1/Cer24:0 (OR ¼ 4.01 [1.93–8.31]) significantly associated with RDKF in multivariable analysis; 124 patients developed ESKD. The ratios Cer16:0/Cer24:0 (hazard ratio [HR] ¼ 3.10 [1.44–6.64]) and Cer24:1/ Cer24:0 (HR ¼ 4.66 [1.93–11.24]) significantly associated with a higher risk of ESKD. The Cer24:1/Cer24:0 ratio improved risk discrimination for ESKD beyond traditional risk factors by small but statistically significant margin (Harrell C-index difference: 0.01; P ¼ 0.022). A high ceramide risk score also associated with RDKF (OR ¼ 2.28 [1.26–4.13]) compared to lower risk score. In conclusion, specific ceramide levels and their ratios are associated with RDKF and conferred an increased risk of ESKD, independently of traditional risk factors, including baseline renal functions in patients with T2D.